The right raise anchor for NorthAI is not recurring revenue. It is Phase III sole-source authority already unlocked under FA8649-21-P-0756. Recurring revenue is the operational expression of that anchor. This memo frames the distinction, maps three valuation scenarios, and builds the diligence-room case before investors ask for it.
Ch 6's central argument is that the right hill is not the biggest hill or the easiest hill. "Concentration beats diversification. One product pursued with full resources beats three products pursued with split attention." NorthAI is approaching a raise discussion without the productization sequence that would justify the multiple. The investor meeting described on the call surfaced this directly: "They asked me, what are the no's?" The correct answer is not a defense of the pitch. It is an honest diagnosis of where NorthAI sits on the productization ladder and a map of what changes the multiple.
The investor question came up precisely on the call: "What are the no's? And I had to think for a second." That pause is diagnostic. When the founder hesitates on the objections, investors hear it as a signal that the objections have not been pre-processed. The correct response to "what are the no's?" is a prepared list that names each objection accurately and reframes it as a solvable sequence.
The right raise anchor for NorthAI is not recurring revenue. Recurring revenue is load-bearing for the multiple, but it is the operational result of something more durable underneath it. The anchor is Phase III sole-source authority under 15 U.S.C. 638(r)(4)(B), already unlocked by FA8649-21-P-0756. That authority lets CHN sign federal contracts without competition, without a J&A, and without a FAR Part 5 synopsis. The recurring revenue flows from those contracts. An investor who sees only the recurring revenue line sees one number. An investor who understands Phase III sees a procurement machine backed by statute.
"The multiples you're gonna receive for a services firm or a low-revenue product firm that hasn't figured out its product market fit and its GTM strategy, it's gonna be a whole lot lower. Than something that's a productized service, right? Even a productized service has much greater multiples than you might imagine."
This is the thesis in one paragraph. Three scenarios quantify it below. Phase III authority is what makes the productized-service revenue defensible against that multiple question.
Source: R6 v1.1 GovCon-AI multiples research, verified against SEC filings and live market data as of 2026-05-28. Palantir corrected to 108x (FY2024 annual revenue basis). BigBear.ai corrected to 13.5x (42% EV decline from $3.07B to $1.77B; revenue held flat at $132M). These corrections matter for how NorthAI frames its ceiling and floor. Phase III sole-source authority is what separates Scenario B from Scenario A at equivalent revenue levels.
Pure Services positioning. Booz Allen at 1.5x EV/Revenue is the ceiling. Leidos at ~1.0x is the floor. Current CHN footprint: $49.5K verified prime, unquantified sub-of-prime history.
Multiple: 0.8-1.5x ARR. At $2-5M estimated ARR, pre-money is $2.5-7.5M. No Phase III contracts signed. Revenue is undifferentiated services billing.
Tech-Enabled Services with Phase III anchor. Level 2 productized service shipped. Phase III CO memo executed. 3-5 agency seats under sole-source contracts. NorthStar v2 or Tech Vector as the first SKU. ARR target $8-12M.
Multiple: 2.5-4.0x ARR. Phase III contracts in the diligence room change the defensibility story. Govini-comparable positioning at early stage.
Productized SaaS with Phase III runway. FedRAMP authorization achieved. 15-20 active federal customers, majority under Phase III authority. Dual federal/commercial revenue mix. ARR target $25-40M.
Multiple: 6-8x ARR (federal-only) to 8-10x (dual federal/commercial). Phase III open-ended value cap means procurement runway is not bounded by a tiered SaaS plan. Govini at 10x ($100M ARR, Oct 2025) is the realistic ceiling.
BigBear.ai traded at 23.2x EV/Revenue in mid-2025. By May 2026, the same company with flat revenue ($132M) trades at 13.5x. The 42% EV collapse is entirely a multiple compression, not a revenue decline. The market repriced a pure federal-AI analytics platform. NorthAI's Scenario C ceiling of $150-320M is credible only with demonstrated commercial-sector pipeline or prime integrator partnerships. A pure-federal-only positioning in 2027-2028 faces the same compression risk. Phase III contracts provide structural defensibility that T&M billing does not. The Defense BD product line is the hedge: if it gains traction with defense prime integrators (Northrop, Raytheon, L3Harris) as customers, the dual-market thesis lifts multiples 20-40%.
Phase III authority is structurally different from a typical pilot-to-production SaaS revenue curve. Most investors reviewing a federal tech company see one number: recurring revenue as a percentage of TTM revenue. That number is load-bearing for the multiple. But recurring revenue alone does not tell the investor whether the revenue is defensible or accidental. A separate narrative section in the diligence room is warranted because Phase III changes three things that recurring revenue metrics do not show.
The diligence-room artifact we would build around Phase III shows three numbers, not one: Phase III contracts in pipeline (qualified, with CO memo in progress), Phase III contracts signed (executed, with associated CLIN and ACV), and recurring revenue from those contracts (trailing twelve months, growth rate). Those three numbers compound. A pipeline entry becomes a signed contract. A signed contract becomes recurring revenue. The recurring revenue percentage rises. The multiple moves.
| Number | What it shows | Why it matters for the raise |
|---|---|---|
| Phase III contracts in pipeline | Qualified opportunities where a CO memo is in progress or a program office contact has confirmed interest. Not LOIs. Documented engagement with a contracting officer who has the authority to obligate. | Shows the procurement machine is running before the raise closes. Pipeline is verifiable through the CO correspondence. Investors can confirm independently. |
| Phase III contracts signed | Executed awards with obligation numbers, CLIN structures, and ACVs. Even one signed Phase III contract at $150-500K demonstrates that a CO obligated under sole-source authority against a NorthAI CLIN. | This is the product-market fit proof for federal-AI investors. It is not a pilot. It is not an LOI. It is a federal obligation backed by statute. Investors who have seen federal tech deals at scale recognize the difference immediately. |
| Recurring revenue from those contracts | Trailing twelve months of billings against Phase III CLINs, with growth rate. Monthly deliverable billing on a productized-service contract counts. SaaS MRR is not required. | Connects the Phase III anchor to the multiple. The recurring revenue percentage moves the valuation from 0.8-1.5x (services) toward 2.5-4.0x (tech-enabled services). The Phase III provenance makes the recurring revenue defensible, not just visible. |
Investors who have seen federal tech deals at scale recognize that sequence immediately. The framing from the call, "sometimes you have to kind of commit to six, 12, 18 months of pain," describes exactly what those three numbers look like at the start. The compounding starts to show by month 9.
These are the investor objections that a prepared founder answers before being asked. Grounded in what surfaced on the discovery call and what the R6 comparables reveal about investor sentiment in federal-AI platforms. Each reframe connects back to the Phase III anchor where applicable.
| Objection | Why investors say it | The reframe |
|---|---|---|
| "Federal procurement cycles are too slow for our fund timeline." | Standard federal-AI objection. 12-18 month sales cycles vs. 3-6 months commercial. Funds with 7-10 year horizons and 4-5 year deployment windows feel squeezed. | Phase III awards do not go through full competition. The CO action memo is the unlock. FA8649-21-P-0756 is already the predicate. GSA Schedule procurement takes 45 days on top of that. SBIR Phase II D2P2 commercialization path is the bridge. Revenue can begin in Year 1 through productized services before FedRAMP authorization. The timeline is staggered, not locked. |
| "You don't have FedRAMP. No FedRAMP means no federal SaaS customers." | Accurate for full SaaS deployment. Investors who understand federal see FedRAMP as a hard gate. | FedRAMP 20x LI-SaaS path (sponsorless, $150-300K, 6-12 months) is the bridge. Prior to FedRAMP: Phase III productized-service contracts (deliverables, not software instances) can be signed and billed today. The Phase III authority does not require FedRAMP. FedRAMP is a Year 2 investment, not Year 0. |
| "You have fans but not buyers. The directed-energy office loved the demo and then went silent." | Ch 6 names this exactly: "fans without procurement authority." Federal end-users are evangelists, not buyers. Contracting officers have the authority; end-users do not. | The fix is productization and vehicle access, not more demos. Phase III authority lets CHN approach a CO directly with the predicate award as justification. Fans become buyers when a mechanism exists for the CO to obligate. The CO action memo creates that mechanism. The engagement sequence changes this. |
| "Your TAM is too small for our check size." | Federal-AI platforms (Govini, Vannevar) at $100M ARR target are $0.5-1B companies. Not $10B. Some funds need $10B+ TAM to deploy meaningful capital. | The addressable market is $7.2B in federal AI obligations (FY2026, +966% YoY). Phase III open-ended value caps mean individual agency relationships are not bounded by subscription tiers. NorthAI's unclassified defense-intelligence analytics position is a $500M-2B TAM depending on how broadly the capability extends. Defense BD (prime integrators as customers) adds a commercial-defense TAM. Govini at $1B valuation on $100M ARR is the realistic ceiling, not the floor. The structural moat that lets CHN reach it faster is the Phase III sole-source authority Govini does not have access to. |
| "We're not sure what the product actually is." | Three product lines (NorthStar, Tech Vector, Defense BD) at different maturity stages without a clear ship order creates investor confusion about where revenue comes from first. | Tech Vector ships first. Single-hill focus per Ch 6. The derives-from argument is textually direct: the Phase I scope was building an AI method to identify commercialization partners for government-funded research via patents, grants, and financial data. That is what Tech Vector does. One CO memo and a program office contact is the mechanism. A Phase III contract on Tech Vector is the product validation proof investors can verify in the diligence room. |
Ch 6 frames the product-readiness signal clearly: "Don't pursue a second product until your first reaches three customers." The same logic applies to fundraising. Raise before these gates and the multiple is Scenario A. Hit the gates and the multiple is Scenario B. The Phase III gate is the hardest to fake and the most credible to show.